Silexion Therapeutics Corp - Ordinary Shares (SLXN)
Healthcare › Biological Products, (No Diagnostic Substances)
Price History
Feb 9, 2026 — Jul 6, 2026Investment Snapshot
- Trading 77% below Graham Number ($21.83) — significant margin of safety
- Piotroski F-Score 3/9 — signs of financial weakness
- Loss-making — negative ROE of -3,516.5%
Silexion Therapeutics Corp - Ordinary Shares (SLXN) is a Healthcare company operating in Biological Products, (No Diagnostic Substances), listed on the NASDAQ , with a market capitalisation of $21 million . Key value metrics: P/E ratio 0.5, P/B ratio 71.42, Piotroski F-Score 3 out of 9 .
Value Score
Key Metrics
Revenue & Net Income
Financial Statements
| Metric | FY22 | FY23 | FY24 |
|---|---|---|---|
| Revenue | $X.XB | $X.XB | $X.XB |
| Gross Profit | $X.XB | $X.XB | $X.XB |
| Operating Income | $X.XB | $X.XB | $X.XB |
| Net Income | $X.XB | $X.XB | $X.XB |
| EBITDA | $X.XB | $X.XB | $X.XB |
| Total Assets | $X.XB | $X.XB | $X.XB |
| Total Liabilities | $X.XB | $X.XB | $X.XB |
Silexion Therapeutics Corp - Ordinary Shares — Fundamental Analysis Summary
Silexion Therapeutics Corp - Ordinary Shares (SLXN) is trading 77% below its Graham Number of $21.83 — a significant margin of safety by Benjamin Graham's standard. The stock carries a low trailing P/E ratio of 0.5x.
On financial health, SLXN shows a weak Piotroski F-Score of 3/9, a signal of deteriorating financial health, and negative return on equity of -3,516.5% (sector average: -20.6%), and manageable leverage with a debt-to-equity ratio of 0.66.
StockPik's composite Value Score for SLXN is 20/100 — reflecting current market or financial concerns. The score is built from ten fundamental signals: P/E, P/B, PEG ratio, P/S ratio, return on equity, gross margin, debt-to-equity, current ratio, dividend yield, and Piotroski F-Score.
SLXN shows earnings growing at 28%.